mRNA structure platform for protein expression with high efficiency

The novel mRNA structure platform with optimized sequences for ζ-globin, black beetle virus, and encephalomyocaditis virus improves protein expression efficiency and stability, addressing the limitations of existing mRNA vaccines by enhancing antigen expression and durability, thus offering superior vaccine and gene therapy performance.

WO2024248367A1PCT designated stage expired Publication Date: 2024-12-05KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006580
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-14
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current mRNA vaccines, such as those from Moderna and Pfizer-BioNTech, have limited durability and effectiveness due to decreased neutralizing antibody titers and increased mutation rates of RNA viruses like SARS-CoV-2, necessitating the development of advanced mRNA structures for sustained antigen expression in immune cells.

Method used

A novel mRNA structure platform incorporating specific base sequences from ζ-globin, black beetle virus, and encephalomyocaditis virus, including optimized 3'-UTR, 5'-UTR, and poly(A) tail designs, enhances protein expression efficiency and stability in various cell types, including immune cells.

Benefits of technology

The new mRNA structure achieves higher and longer-lasting protein expression compared to existing mRNA constructs, making it suitable for improved vaccine development and gene therapy applications, including sustained immune response and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006580_05122024_PF_FP_ABST
    Figure KR2024006580_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an mRNA structure platform capable of expressing a protein with high efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

mRNA construct platform for high-efficiency protein expression

[0001] Cross-citation with related applications

[0002] This application claims the benefit of priority from Korean Patent Application No. 2023-0068278, filed May 26, 2023, the entire contents of which are incorporated herein by reference.

[0003] Technology field

[0004] The present invention relates to an mRNA structure platform capable of expressing a protein with high efficiency.

[0005] As COVID-19, an infection caused by the novel coronavirus SARS-CoV-2 that broke out in 2019, rapidly spread worldwide, vaccine development was competitively conducted at the national level to prevent further spread and reduce the number of deaths. Among various vaccine development strategies, mRNA vaccines, which are classified as relatively new strategies, were approved for use in the shortest period of time and are currently being administered. The mRNA vaccine is a nucleic acid-based vaccine that enhances adaptive immunity using artificially synthesized mRNA (messenger RNA, a blueprint containing antigen protein information). mRNA containing the viral antigen gene is synthesized in vitro, purified to high purity, and administered to the human body in the form of LNP (lipid nanoparticle). The antigen expressed by immune cells is presented outside the cells, inducing various antigen-specific adaptive immunity.

[0006] In December 2020, mRNA vaccines from Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2) received emergency use authorization in the United States and other major countries, and a large-scale clinical trial with over 30,000 participants confirmed an impressive efficacy rate of over 95%, which is in stark contrast to the 50-70% rate of traditional vaccines. Despite the unprecedented success of mRNA vaccines, the short-term efficacy of the vaccines necessitates booster shots. Furthermore, neutralizing antibodies and vaccine efficacy decline over time after vaccination. Both Moderna and Pfizer-BioNTech mRNA vaccines have been reported to show a more than sixfold decrease in neutralizing antibodies 6-8 months after the second dose.

[0007] Furthermore, the continued emergence of mutant viruses due to the prolonged COVID-19 pandemic is another factor reducing the effectiveness of mRNA vaccines. As an RNA virus, SARS-CoV-2 naturally undergoes numerous mutations during its replication process. If mutations occur in the region where neutralizing antibodies are activated, neutralizing antibodies will fail, reducing or even eliminating vaccine efficacy.

[0008] Therefore, to enhance the sustained efficacy of mRNA vaccines, it is necessary to develop advanced mRNA constructs that can enhance antigen expression in antigen-presenting immune cells and maintain it for a longer period of time than first-generation mRNA vaccines. In particular, sustained high expression, not only in inactive antigen-presenting immune cells but also in activated antigen-presenting immune cells after migration to lymph nodes, is believed to be crucial for activating adaptive immunity.

[0009] Meanwhile, the mRNA is currently being actively applied in research for the development of vaccines for not only infectious diseases but also cancer, and it is expected that its application will expand in the future to develop treatments for various rare genetic diseases and intractable diseases.

[0010] This method delivers disease-causing genes to cells and living organisms in the form of mRNA to supplement the amount or activity of proteins, thereby producing a therapeutic effect. It is the most suitable method for genetic diseases caused by a decrease in the amount or activity of genes with a clearly proven correlation with the disease, and among them, monogenic diseases caused by defects in a single gene.

[0011] The development of vaccines or therapeutics using mRNA, as described above, directly delivers disease-causing genes, resulting in high target specificity. Furthermore, because it utilizes RNA, it is not integrated into the genome but rather transiently expressed, ensuring high safety. Furthermore, once the mRNA structure and delivery module are established, it can be readily applied to a variety of disease genes. Furthermore, its efficient production and process, coupled with its short overall development period, enable economical pharmaceutical development and facilitate the development of low-cost drugs. Furthermore, it is highly suitable for the development of personalized treatments in the future.

[0012] Recently, several gene therapies using adeno-associated virus (AAV)-based delivery methods have been approved as new drugs. Representative examples include Zolgensma for spinal muscular atrophy, Zynteglo for anemia, and Hemgenix for hemophilia. These drugs are priced at an astronomical 2.5-4.5 billion won per dose. Despite the advantage of delivering multi-year therapeutic effects with a single administration, these therapies are still considered to have limitations, including the packaging capacity of AAV vectors, which limits the size of the gene. Furthermore, these therapies are still unrealistically high, have a significant immune response, and lack of efficacy in patients exposed to the AAV virus due to the formation of neutralizing antibodies.

[0013] In contrast, mRNA-based therapeutics theoretically have no limitations on the size of the target gene, are highly safe, allow for relatively low drug prices due to economical drug production, and have no restrictions on patient populations, which can complement the weaknesses of AAV-based therapies. Despite these advantages, for mRNA-based therapeutics to be successful as therapeutics, high and sustained expression of the disease gene for a long period of time is essential. This is because, unlike vaccines, which express sufficient antigens with a single administration and form an immune memory through an in vivo immune response, for therapeutics, sustained high expression of the disease protein is crucial for therapeutic efficacy.

[0014] Therefore, the development of an mRNA structure platform capable of expressing proteins with high efficiency can not only be applied to the effective and rapid development of mRNA vaccines that can overcome SARS-CoV-2, various high-risk viruses (Zika, influenza, SFTS, Dengue, etc.), and future emerging new variant virus epidemics, but it is also an essential process that enables the development of mRNA-based gene therapy.

[0015] One object of the present invention is to provide a novel mRNA structure that can be applied as a platform capable of expressing a target protein with high efficiency.

[0016] Another object of the present invention is to provide a pharmaceutical composition comprising the novel mRNA structure.

[0017] In order to achieve the above object, one aspect of the present invention comprises: a base sequence encoding a target protein; a base sequence of 3'-UTR of ζ-globin arranged downstream of the base sequence encoding the target protein; and (A) arranged downstream of the base sequence of 3'-UTR of ζ-globin 60Provided is an mRNA structure comprising a base sequence comprising a repeating unit of G)n (wherein n is an integer from 1 to 3).

[0018] The mRNA structure may further include a base sequence derived from BBV (black beetle virus) or PPRV (peste des petits ruminants virus) located upstream of the base sequence encoding the target protein.

[0019] The above mRNA structure may further include a base sequence of an IRES (internal ribosome entry site) of EMCV (encephalomyocaditis virus) between the downstream of the base sequence encoding the target protein and the upstream of the base sequence of the 3'-UTR of ζ-globin.

[0020] In addition, to achieve the above purpose, another aspect of the present invention provides a pharmaceutical composition comprising the mRNA structure.

[0021] The above pharmaceutical composition may be a vaccine or a gene therapy agent.

[0022] The mRNA structure newly designed and derived in the present invention has a much superior expression efficiency in cells compared to the mRNA structures commercialized previously by Moderna or Pfizer-BioNTech, and thus has the advantage of being usefully applied as a platform technology that can be widely utilized in the development of mRNA-based vaccines or therapeutics.

[0023] However, the effects of the present invention are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description below.

[0024] Figure 1 shows the design of mRNA constructs by applying the base sequences of various cellular genes to the 3'-UTR in order to derive the optimal 3'-UTR (A), the results of measuring the activity of nanoluciferase over time after transfecting these mRNA constructs into 293T cells (B), and the results of analyzing the change in relative activity by correcting the activity of the nanoluciferase to the 12-hour result (C).

[0025] Figure 2 also shows the results of designing mRNA structures by applying various viral-derived base sequences to 3'-UTRs to derive the optimal 3'-UTR (A), measuring the activity of nanoluciferase over time after transfecting 293T cells with these mRNA structures (B), and analyzing the change in relative activity by correcting the activity of the nanoluciferase to the 12-hour result (C).

[0026] Figure 3 also shows the design of mRNA structures by applying a base sequence in which guanines are inserted in various numbers and intervals into the poly(A) tail to derive the optimal poly(A) tail (A), the results of measuring the activity of nanoluciferase over time after transfecting these mRNA structures into 293T cells (B), and the results of analyzing the change in relative activity by correcting the activity of the nanoluciferase to the 12-hour result (C).

[0027] Figure 4 shows a 3'-UTR in which the base sequence of ζ-globin's 3'-UTR or the base sequence of EMCV's IRES is applied singly or in combination, and A is applied as a poly(A) tail. 60 The results of designing mRNA structures by applying G2 (A), measuring the activity of nanoluciferase over time after transfecting these mRNA structures into 293T cells (B), and analyzing the change in relative activity by correcting the activity of the nanoluciferase to the 12-hour result (C) are shown.

[0028] Figure 5 shows a method for deriving the optimal 5'-UTR by applying a combination of the base sequence of the 3'-UTR of ζ-globin or the base sequence of the IRES of EMCV and the base sequence of the 3'-UTR of ζ-globin to the 3'-UTR, and using A as the poly(A) tail. 60 While applying G2, mRNA constructs were designed by applying various base sequences to the 5'-UTR (A), and the results of measuring the activity of nanoluciferase over time after transfecting these mRNA constructs into 293T cells (B) and analyzing the change in relative activity by correcting the activity of the nanoluciferase to the 12-hour result (C) are shown.

[0029] Figure 6 shows the three mRNA structures (CJ-1, BBV+ζG+A) showing the highest expression efficiency in Figure 5. 60 G 2; , CJ-2, PPRV+ζG+A 60 G 2; CJ-3, BBV+EMCV+ζG+A 60 G2) was selected, and additional mRNA constructs used in the development of the coronavirus mRNA vaccine by Moderna and Pfizer-BioNTech were produced (A), and these mRNA constructs were transfected into THP-1 cells (B), which are monocytic immune cells, mouse DC2.4 cells (C), which are dendritic cell lines, and cells activated with LPS (Activated DC2.4 Cells) (D), and the results of measuring the activity of nanoluciferase over time are shown.

[0030] Figure 7 shows the results of measuring nanoluciferase activity over time after transfection of three types of mRNA constructs (CJ-1, CJ-2, CJ-3) into C2C12 cells (A), which are representative mouse muscle cells; Huh-7 cells (B), which are representative hepatocytes; A549 cells (C), which are representative lung cells; AREP-19 cells (D), which are representative retinal cells; SH-SY5Y cells (ATCC) and Neuro-2a cells (ATCC), which are representative neural cells; and 293T cells.

[0031] Figure 8 shows the results of measuring nanoluciferase activity over time (C) after transfection of three types of mRNA constructs (CJ-1, CJ-2, CJ-3) into 293T cells (A), HepG2 cells (B), which are another representative hepatocyte, SH-SY5Y cells (C), and Neuro-2a cells (D), which are representative neural cells.

[0032] Hereinafter, the present invention will be described in detail.

[0033] 1. Novel mRNA structure

[0034] One aspect of the present invention provides a novel mRNA structure.

[0035] The mRNA structure of the present invention comprises a base sequence encoding a target protein; a base sequence of 3'-UTR (3'-untranslated region) of ζ-globin; and (A 60 G) n A base sequence comprising a repeating unit;

[0036] The above target protein refers to a target protein to be expressed through the mRNA construct of the present invention. Specifically, the target protein may refer to a protein that is directly translated and expressed from the mRNA construct of the present invention by the cell's own translation system after the mRNA construct of the present invention is introduced into the cell. Accordingly, the 'base sequence encoding the target protein' included in the mRNA construct of the present invention may refer to a CDS (coding sequence) that is composed only of exons with introns removed and can be directly translated to produce the target protein.

[0037] The above ζ-globin is a human HBZ gene, one of five genes belonging to the human α-globin gene cluster. The base sequence of the 3'-UTR of the ζ-globin refers to the base sequence of the 3'-UTR included in the mRNA produced in the process of expression of the human HBZ gene. In particular, the base sequence of the 3'-UTR of the ζ-globin may include the base sequence of SEQ ID NO: 6 or a variant thereof, and specifically, the base sequence of the 3'-UTR of the ζ-globin may be composed of the base sequence of SEQ ID NO: 6 or a variant thereof. The variant of the base sequence of the above sequence number 6 refers to those having a sequence homology of 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the base sequence of the above sequence number 6, but is not limited thereto, and refers to all base sequences that have the function of improving the stability and expression efficiency of mRNA, like the base sequence of the above sequence number 6.

[0038] The base sequence of the 3'-UTR of the above ζ-globin can be positioned downstream of the base sequence encoding the target protein, and in particular, can be operably linked to the base sequence encoding the target protein.

[0039] Above (A 60 G) n The base sequence containing the repeating unit is a variant of the poly(A) tail, and the above (A 60 G) n The base sequence containing the repeating unit may have a length of 115 nt to 125 nt, for example, may have a length of 117 nt to 123 nt, and in particular, the above (A 60 G) n The base sequence including the repeating unit may have a length of 121 nt. Accordingly, n may be an integer from 1 to 3, for example, an integer from 1 to 2, and in particular, n may be 1. Specifically, the (A 60 G)n The base sequence containing the repeating unit is the base sequence of sequence number 21 (A 57 GA 60 It could be GAA).

[0040] Above (A 60 G) n The base sequence including the repeating unit can be positioned downstream of the base sequence of the 3'-UTR of the ζ-globin, and in particular can be operably linked to the base sequence encoding the target protein and the base sequence of the 3'-UTR of the ζ-globin.

[0041] Meanwhile, the mRNA structure of the present invention may further include a base sequence of a 5'-UTR of BBV (black beetle virus) or a base sequence of a 5'-UTR of PPRV (peste des petits ruminants virus). The base sequence of the 5'-UTR of BBV is a sequence derived from a virus that infects black beetles and is located upstream of the coding sequence, thereby improving protein translation efficiency. In particular, the base sequence of the 5'-UTR of BBV is much shorter than the IRES base sequence known as a Cap-independent translation mechanism, but exhibits high protein translation efficiency. In addition, the PPRV belongs to the genus Morbillivirus of the Paramyxoviridae family and is a pseudoruddy disease virus that mainly infects goats and sheep. It is estimated that the base sequence of the 5'-UTR of the above PPRV is present upstream of the F gene of PPRV and complementarily binds to 18S rRNA, thereby improving protein translation efficiency.

[0042] The base sequence of the 5'-UTR of the above BBV (black beetle virus) may include the base sequence of SEQ ID NO: 24 or a variant thereof, and specifically, the base sequence of the 5'-UTR of the BBV may be composed of the base sequence of SEQ ID NO: 24 or a variant thereof. In addition, the base sequence of the 5'-UTR of the above PPRV may include the base sequence of SEQ ID NO: 25 or the base sequence of SEQ ID NO: 26 or a variant thereof, and specifically, the base sequence of the 5'-UTR of the above PPRV may be composed of the base sequence of SEQ ID NO: 25 or the base sequence of SEQ ID NO: 26 or a variant thereof. The variant of the base sequence of the above sequence number 24, 25 or 26 refers to those having a sequence homology of 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more or 99% or more with the base sequence of the above sequence number 24, 25 or 26, but is not limited thereto, and refers to all base sequences that have the function of improving the stability and expression efficiency of mRNA, like the base sequence of the above sequence number 24, 25 or 26.

[0043] The base sequence of the 5'-UTR of the above BBV or the base sequence of the 5'-UTR of the PPRV can be positioned upstream of the base sequence encoding the target protein, and in particular, can be operably linked to the base sequence encoding the target protein.

[0044] In addition, the mRNA structure of the present invention may further include a base sequence of an internal ribosome entry site (IRES) of EMCV (encephalomyocaditis virus). The base sequence of the IRES of EMCV may be composed of a base sequence of SEQ ID NO: 13 or a variant thereof. The variant of the base sequence of SEQ ID NO: 13 refers to those having a sequence homology of 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the base sequence of SEQ ID NO: 13, but is not limited thereto, and refers to all base sequences that function to improve the stability and expression efficiency of mRNA, such as the base sequence of SEQ ID NO: 13.

[0045] The base sequence of the IRES of the EMCV can be positioned between the downstream of the base sequence encoding the target protein and the upstream of the base sequence of the 3'-UTR of the ζ-globin, and in particular, can be operably linked to the base sequence encoding the target protein and the base sequence of the 3'-UTR of the ζ-globin.

[0046] The mRNA construct of the present invention, configured as described above, has excellent stability and expression efficiency within cells, and thus has the effect of maintaining a high expression state within cells for a long period of time even after transfection. In particular, according to a specific embodiment of the present invention, it was confirmed that not only did it show a higher expression efficiency than the existing mRNA constructs of Moderna or Pfizer-BioNTech, but it was also confirmed that it consistently showed a high expression efficiency regardless of various cell types such as muscle cells, liver cells, lung cells, eye cells, and nerve cells (see Figures 6 to 8).

[0047] 2. Utilization of novel mRNA structures

[0048] As described above, the novel mRNA structure of the present invention exhibits high expression efficiency in cells, and thus can be transfected into cells for expression of a target protein.

[0049] In addition, the novel mRNA structure of the present invention, which can be transfected into cells as described above, can be used as an active ingredient of a pharmaceutical composition depending on the target protein.

[0050] For example, if the target protein is a virus- or bacteria-derived protein, the pharmaceutical composition comprising the mRNA construct of the present invention may be a vaccine. In this case, the target virus- or bacteria-derived protein is expressed with high efficiency by the novel mRNA construct within the subject injected with the pharmaceutical composition of the present invention, and the virus- or bacteria-derived protein thus expressed is recognized as an antigen within the subject, inducing an immune response, thereby functioning as a vaccine.

[0051] In addition, if the target protein is a causal protein deficient in a specific disease such as cancer or a genetic disease, the pharmaceutical composition comprising the mRNA construct of the present invention may be a gene therapy agent. In this case, the target protein, which is a causal protein deficient in the specific disease, is expressed with high efficiency by the novel mRNA construct in the subject injected with the pharmaceutical composition of the present invention, and the deficiency of the causal protein is complemented by the high-efficiency expression of the causal protein, thereby treating the specific disease. Therefore, any disease that can be treated by complementing the deficient gene can be treated by the pharmaceutical composition of the present invention without any particular limitation.

[0052] In particular, the diseases most suitable for application as gene therapy as described above are monogenic genetic diseases caused by a single gene defect, such as spinal muscular atrophy (SMA), a rare neuromuscular disease, and cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), Friedreich's ataxia (FA), hemophilia, Rett syndrome, Fabry disease, and sickle cell disease.

[0053] Moreover, the mRNA construct of the present invention consistently exhibits high expression efficiency regardless of various cell types, such as muscle cells, liver cells, lung cells, ophthalmic cells, and nerve cells, and thus can be applied to various cells that may induce various diseases. Therefore, when the mRNA construct of the present invention is used as an active ingredient of a gene therapy agent as described above, it has the advantage of ensuring a much better therapeutic effect compared to when using the existing mRNA constructs of Moderna or Pfizer-BioNTech.

[0054] Meanwhile, when the mRNA structure of the present invention is used as an active ingredient of a pharmaceutical composition as described above, the pharmaceutical composition may further include a delivery means for delivering the mRNA structure of the present invention.

[0055] Representative examples of the above delivery means include nanoparticles such as liposomes or LNPs (lipid nanoparticles), and the liposomes or LNPs include cationic lipids, non-cationic lipids, or neutral lipids, and may additionally include other lipids such as PEG (polyethylene glycol) or cholesterol. In addition, exosomes may also be used as nanoparticles that serve as the above delivery means, and cationic biocompatible polymers or cationic peptides (e.g., protamine, cell penetrating peptides (CPPs)) that can provide improved stability by electrostatically interacting with the mRNA structure of the present invention may be used as other delivery means, but the present invention is not limited thereto, and any and all means known in the technical field to which the present invention pertains that can deliver the mRNA structure may be used.

[0056] In addition, the pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers. The pharmaceutically acceptable carrier must be compatible with the active ingredient of the present invention, and may be used as a mixture of saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into an injectable formulation such as an aqueous solution, suspension, or emulsion. In particular, it is preferable to provide the composition in a lyophilized form. A method commonly known in the art to which the present invention pertains can be used to manufacture a lyophilized formulation, and a stabilizer for lyophilization may be added. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or a method disclosed in Remington's pharmaceutical Science (Mack Publishing company, Easton PA).

[0057] The content and administration method of the active ingredients, etc. included in the above pharmaceutical composition can be determined by a person skilled in the art based on the symptoms and severity of the disease of a typical patient. Furthermore, the composition can be formulated in various forms, such as powders, tablets, capsules, liquids, injections, ointments, and syrups, and can also be provided in unit-dose or multi-dose containers, such as sealed ampoules and bottles.

[0058] In addition, the pharmaceutical composition can be administered orally or parenterally. The route of administration of the composition according to the present invention is not limited to these, but for example, bronchial, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, enteral, sublingual, or topical administration is possible. The dosage of the composition according to the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, method, excretion rate, or disease severity, and can be easily determined by a person skilled in the art. In addition, the pharmaceutical composition can be formulated into a suitable dosage form using a known technique for clinical administration.

[0059] Hereinafter, the present invention will be described in detail by examples.

[0060] However, the following examples specifically illustrate the present invention, and the content of the present invention is not limited by the following examples.

[0061] [Example 1]

[0062] Structure of a novel mRNA construct

[0063] In order to derive a novel mRNA structure with high stability and translation efficiency in a linear form within cells, first, nanoluciferase, which has the highest luminescence and smallest protein size among reporter proteins, and nanoluciferase-PEST fusion protein, in which PEST amino acid is fused to the C-terminus of the nanoluciferase, were determined as target proteins to be expressed. Then, based on the base sequence of SEQ ID NO: 1 encoding the nanoluciferase-PEST fusion protein, the base sequence of the 5'-UTR is arranged upstream thereof, and CleanCap (TriLink) in the form of Cap1 is arranged at the 5'-terminus of the base sequence of the 5'-UTR, while the base sequence of the 3'-UTR and the base sequence of the poly(A) tail are sequentially arranged downstream thereof, thereby specifying the structure of the novel mRNA structure.

[0064] [Example 2]

[0065] Selection of optimal components for novel mRNA structures

[0066] [2-1] Selection of the optimal 3'-UTR

[0067] First, in order to derive the optimal 3'-UTR, in the specific mRNA structure in Example 1, the base sequence of the 5'-UTR was fixed to the base sequence of the 5'-UTR of human α-globin (base sequence of SEQ ID NO: 2) and the base sequence of the poly(A) tail was fixed to a poly(A) sequence of 117 nt, while applying the base sequences of various types of 3'-UTRs disclosed in Table 1 below as the base sequence of the 3'-UTR, thereby designing six types of mRNA structures of Preparation Examples 1-1 to 1-6 as shown in A of FIG. 1.

[0068] 적용 제조예 #명칭염기서열(5'->3')서열번호1-1α-globinGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCA (111bp)31-2β-globinGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAA (134bp)41-3γ1-globinGCTCACTGCCCATGATTCAGAGCTTTCAAGGATAGGCTTTATTCTGCAAGCAATACAAATAATAAATCTATTCTGCTGAGAGATCACACA (90bp)51-4ζ-globinGCGCCGCCTCCGGGACCCCCAGGACAGGCTGCGGCCCCTCCCCCGTCCTGGAGGTTCCCCAGCCCCACTTACCGCGTAATGCGCCAATAAACCAATGAACGAA (103bp)61-5Tyrosine hydroxylaseGTGCACGGCGTCCCTGAGGGCCCTTCCCAACCTCCCCTGGTCCTGCACTGTCCCGGAGCTCAGGCCCTGGTGAGGGGCTGGGTCCCGGGTGCCCCCCATGCCCTCCCTGCTGCCAGGCTCCCACTGCCCCTGCACCTGCTTCTCAGCGCAACAGCTGTGTGTGCCCGTGGTGAGGTTGTGCTGCCTGTGGTGAGGTCCTGTCCTGGCTCCCAGGGTCCTGGGGGCTGCTGCACTGCCCTCCGCCCTTCCCTGACACTGTCTGCTGCCCCAATCACCGTCACAATAAAAGAAACTGTGGTCTCTA (304bp)71-6InsulinACGCAGCCCGCAGGCAGCCCCACACCCGCCGCCTCCTGCACCGAGAGAGATGGAATAAAGCCCTTGAACCAGC (73bp)8

[0069] The mRNA constructs of Manufacturing Examples 1-1 to 1-6 designed as described above were connected to the downstream of the T7 promoter of a DNA vector (pcDNA3.1 hygro Vector), and a type II restriction enzyme recognition sequence was inserted so that it was placed immediately after the poly(A) tail of the mRNA construct. Therefore, the mRNA construct expressed from the DNA vector as described above has the 5'-end capped with CleanCap, and the 3'-end is a pure adenine sequence of 117 nt in length. The DNA vector was linearized by treating 5 ug of the DNA vector manufactured as described above with the type IIS restriction enzyme BspQI (NEB) and reacting overnight, and whether the DNA vector was completely cut was confirmed through electrophoresis using an agarose gel, and then the enzymes and buffer solutions used in the linearization process were transferred to a glass fiber membrane (Expin). TMUsing CleanUP SV, GeneAll, only linearized DNA was isolated and purified. In vitro transcription was performed at 37°C for 4 hours using 500 ng of linear DNA isolated and purified as described above, followed by DNase treatment and incubation at 37°C for 30 minutes to remove the DNA used in the reaction. Then, only the mRNA generated as a result of in vitro transcription was isolated and purified using a silica column (HiYield RNA UltraPurification Kit, RealBiotechCorporation (RBC)). The mRNA separated and purified as above was denatured at 70 degrees Celsius for 10 minutes, and then electrophoresis was performed using an agarose gel to confirm that the mRNAs were uniformly produced in the expected size. In addition, the purity and concentration of the produced mRNA were measured using a nanodrop device (spectrophotometer, ND-2000, ThermoScientific). Then, Lipofectamine 2000 TM Transfection Reagent, ThermoFisher) was used for reverse transfection, 1x10 in a 96-well plate. 4 293T cells (ATCC) were divided into 10 cells / well at a concentration of 10 cells / well and transfected with the mRNA isolated and purified as described above, and Nano-Glo reagent (Nano-Glo (R) Nanoluciferase activity was measured 6, 12, 24, 48, 72, and 96 hours after transfection using the Luciferase Assay System (Promega).

[0070] As a result, as shown in B and C of Fig. 1, it was confirmed that the expression of nanoluciferase was highest and lasted the longest in the mRNA construct of Manufacturing Example 1-4 that applied the 3'-UTR of human ζ-globin.

[0071] Meanwhile, in the specific mRNA structure of Example 1, the base sequences of ENE, an RNA stabilizing sequence of Kaposi's herpesvirus (KSHV) disclosed in Table 2 below, and IRES (internal ribosome entry site) of various RNA viruses were applied as the base sequence of 3'-UTR, to design seven mRNA structures of Manufacturing Examples 1-7 to 1-13 as shown in A of FIG. 2.

[0072] 적용 제조예 #명칭염기서열(5'->3')서열번호1-71X ENETGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAGCTCAAATTAAACTAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTAATCCATA (190bp)91-82X ENETGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTTGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAGCTCAAATTAAACTAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTAATCCATA (269bp)101-93X ENETGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTTGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTTGTTTTGGCTGGGTTCTTCCTTGTTCGCACCGGACACCTCCAGTGACCAGACGGCAAGGTTCTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAGCTCAAATTAAACTAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTAATCCATA(348bp)111-10CVB3TTAAAACAGCCTGTGGGTTGATCCCACCCACAGGGCCCATTGGGCGCTAGCACTCTGGTATCACGGTACCTTTGTGCGCCTGTTTTATACCCCCTCCCCCAACTGTAACTTAGAAGTAACACACACCGATCAACAGTCAGCGTGGCACACCAGCCACGTTTTGATCAAGCACTTCTGTTACCCCGGACTGAGTATCAATAGACTGCTCACGCGGTTGAAGGAGAAAGCGTTCGTTATCCGGCCAACTACTTCGAAAAACCTAGTAACACCGTGGAAGTTGCAGAGTGTTTCGCTCAGCACTACCCCAGTGTAGATCAGGTCGATGAGTCACCGCATTCCCCACGGGCGACCGTGGCGGTGGCTGCGTTGGCGGCCTGCCCATGGGGAAACCCATGGGACGCTCTAATACAGACATGGTGCGAAGAGTCTATTGAGCTAGTTGGTAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACTGCGGAGCACACACCCTCAAGCCAGAGGGCAGTGTGTCGTAACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCGTGTTTCATTTTATTCCTATACTGGCTGCTTATGGTGACAATTGAGAGATTGTTACCATATAGCTATTGGATTGGCCATCCGGTGACTAATAGAGCTATTATATATCCCTTTGTTGGGTTTATACCACTTAGCTTGAAAGAGGTTAAAACATTACAATTCATTGTTAAGTTGAATACAGCAAA(742bp)121-11EMCVCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACC (586bp)131-12HCVGGCGACACTCCACCATAGATCACTCCCCTGTGAGGAACTACTGTCTTCACGCAGAAAGCGTCTAGCCATGGCGTTAGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGGAATTGCCAGGACGACCGGGTCCTTTCTTGGATTAACCCGCTCAATGCCTGGAGATTTGGGCGTGCCCCCGCGAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCCTTGTGGTACTGCCTGATAGGGTGCTTGCGAGTGCCCCGGGAGGTCTCGTAGACCGTGCATCATGAGCACAAATCCTAAACCTCAAAGAAAAACC(357bp)141-13CrPVAAAGCAAAATGTGATCTTGCTTGTAAATACAATTTTGAGAGGTTAATAAATTACAAGTAGTGCTATTTTTGTATTTAGGTTAGCTATTTAGCTTTACGTTCCAGGATGCCTAGTGGCAGCCCCACAATATCCAGGAAGCCCTCTCTGCGGTTTTTCAGATTAGGTAGTCGAAAACCTAAGAAATTTA (189bp)15

[0073] The mRNA constructs of Manufacturing Examples 1-7 to 1-13 designed as described above were inserted into a DNA vector in the same manner as the mRNA constructs of Manufacturing Examples 1-1 to 1-6, and then transcribed in vitro. The produced mRNA was transfected into 293T cells to measure nanoluciferase activity. As a result, as shown in B and C of Fig. 2, it was confirmed that the expression of nanoluciferase was the highest and lasted the longest in the mRNA construct of Manufacturing Example 1-11 to which the IRES of EMCV was applied. [2-2] Selection of the optimal poly(A) tail

[0074] According to a recent report that mRNA stability can be further improved when the poly(A) tail is composed of a mixture of guanosine (G) compared to when it is composed of only adenosine (A), in the specific mRNA structure in Example 1, excluding the base sequence of the 3'-UTR, various types of base sequences disclosed in Table 3 below were applied as the base sequence of the poly(A) tail, thereby designing six types of mRNA structures of Preparation Examples 2-1 to 2-6 as shown in A of FIG. 3.

[0075] Application Manufacturing Example #Name Base Sequence (5'->3') Sequence Number 2-1A10-G11A9GA 10 GA 10 GA 10 GA 10 GA 10 GA 10 GA 10 GA 10 GA 10 GA10 GAA162-2A20-G6A 13 GA 20 GA 20 GA 20 GA 20 GA 20 GAA172-3A30-G4A 25 GA 30 GA 30 GA 30 GAA182-4A40-G3A 36 GA 40 GA 40 GAA192-5A50-G3A 16 GA 50 GA 50 GAA202-6A60-G2A 57 GA 60 GAA21

[0076] The mRNA constructs of Manufacturing Examples 2-1 to 2-6 designed as described above were inserted into a DNA vector in the same manner as in Example [2-1], transcribed in vitro, and the produced mRNA was transfected into 293T cells to measure nanoluciferase activity. As a result, as shown in B and C of FIG. 3, among various sequences, it was confirmed that the expression of nanoluciferase was the highest and lasted the longest in the mRNA construct of Manufacturing Example 2-6, which applied a modified poly(A) tail (A60-G2) in which two guanosines (G) were inserted at intervals of 60 nt.

[0077] [2-3] Selection of the optimal combination downstream of the base sequence encoding the target protein

[0078] In addition, in order to select the optimal combination downstream of the base sequence encoding the target protein, in the specific mRNA structure of Example 1, the modified poly (A) tail (A60-G2) selected in Example 2-2 was applied as the base sequence of the poly (A) tail, while the base sequence of the 3'-UTR of ζ-globin selected in Example 2-1 (base sequence of SEQ ID NO: 6) and the base sequence of the IRES of EMCV (base sequence of SEQ ID NO: 13) were applied in combination as in FIG. 4A, thereby designing six mRNA structures of Preparation Examples 3-1 to 3-6 as shown in FIG. 4A.

[0079] The mRNA constructs of Manufacturing Examples 3-1 to 3-6 designed as described above were inserted into a DNA vector in the same manner as in Example [2-1], then transcribed in vitro and the produced mRNA was transfected into 293T cells to measure nanoluciferase activity.

[0080] As a result, as shown in B and C of Fig. 4, it was confirmed that the expression of nanoluciferase was the highest and sustained for the longest time in the mRNA construct of Preparation Example 3-4, in which the 3'-UTR of ζ-globin was applied alone. In addition, when combined with the IRES of EMCV, it was confirmed that excellent sustained expression of nanoluciferase could be achieved in the mRNA construct of Preparation Example 3-5, in which the IRES of EMCV was positioned upstream of the 3'-UTR of ζ-globin.

[0081] [2-4] Selection of the optimal 5'-UTR

[0082] Meanwhile, in order to derive the optimal 5'-UTR, in the specific mRNA structure in Example 1, the 3'-UTR was fixed to the base sequence of the 3'-UTR of ζ-globin (mRNA structures of Preparation Examples 4-1 to 4-5) or a combination of the base sequence of the IRES of EMCV and the 3'-UTR of ζ-globin (mRNA structures of Preparation Examples 4-6 to 4-10), and the poly(A) tail was fixed to the modified poly(A) tail of A60-G2, while applying the base sequences of various types of 5'-UTRs disclosed in Table 4 below as the base sequence of the 5'-UTR, thereby designing 10 types of mRNA structures of Preparation Examples 4-1 to 4-10 as shown in A of FIG. 5.

[0083] Application Manufacturing Example #Name Base Sequence (5'->3') Sequence Number 4-1, 4-61-23bCAGCGGAAACGAGCGAAAAAAAAACAGCGGAAACGAGCGAAAAAAAAACAGCGGAAACGAGCGAAAAAAAAACAGCGGAAACGAGCGAAAAAAAAACAGCGGAAACGAGCGAAAAAAACAGCGGAAACGAGCGAGAGAGAACCCCTTAAGACC (131bp) 224-2, 4-717.2TCCGGTCGTAAAAAAAAATCCGGTCGTAAAAAAAAATCCGGTCGTAAAAAAAAATCCGGTCGTAAAAAAAAATCCGGTCGTAAAAAAAAATCCGGTCGTAAAAAAAAATCCGGTCGTAGAGAGAACCCCTTAAGACC (101bp) 234-3, 4-8BBVGTTTTCGAAACAAATAAAACAGAAAAGCGAACCTAAACA (39bp) 244-4, 4-9PPRVAGGGGCCAAGTCCATACGACAGGCCCCAGCCCGCCAGACGGAGGGCCGCAGAAAGGAAGGAGACACGACCGCCCCAGAAGGAGGA (85bp)254-5, 4-10ΔPPRVGCCCGCCAGACGGAGGGCCGCAGAAAGGAAGGAGACACGACCGCCCCAGAAGGAGGA (57bp)26

[0084] The mRNA constructs of Manufacturing Examples 4-1 to 4-10 designed as described above were inserted into a DNA vector in the same manner as in the above Example [2-1], then transcribed in vitro, and the generated mRNA was transfected into 293T cells to measure nanoluciferase activity. As a result, as shown in B and C of Fig. 5, in both cases where the base sequence of the 3'-UTR of ζ-globin was used as the 3'-UTR, or where a combination of the base sequence of the IRES of EMCV and the 3'-UTR of ζ-globin was used as the 3'-UTR, the expression of nanoluciferase was the highest in the mRNA constructs of Manufacturing Examples 4-3 and 4-8 that applied the base sequence of the 5'-UTR of BBV, and in the mRNA constructs of Manufacturing Examples 4-4, 4-5, 4-9, and 4-10 that applied the base sequence of the 5'-UTR of PPRV. It was confirmed to have lasted for a long time.

[0085] [Example 3]

[0086] Derivation and evaluation of optimal mRNA structures

[0087] By combining the optimal elements selected in the above [Example 2], in the specific mRNA structure in the above Example 1, i) the base sequence of the 5'-UTR of BBV (SEQ ID NO: 24) or the base sequence of the 5'-UTR of PPRV (SEQ ID NO: 25) as the 5'-UTR, ii) the base sequence of the 3'-UTR of ζ-globin (SEQ ID NO: 6) or the combination of the base sequence of the IRES of EMCV and the base sequence of the 3'-UTR of ζ-globin (SEQ ID NO: 13 + SEQ ID NO: 6) as the 3'-UTR, and iii) the modified poly(A) tail of A60-G2 (SEQ ID NO: 21) as the poly(A) tail, three mRNA structures (BBV+ζG+A) as shown in A of FIG. 6 60 G2; CJ-1, PPRV+ζG+A 60 G2; CJ-2, BBV+EMCV+ζG+A 60G2; CJ-3) were produced. Then, the three types of mRNA structures described above were evaluated by comparing them with the existing commercially available mRNA structures of Moderna and Pfizer-BioNTech.

[0088] First, considering the case where the mRNA structure is applied to vaccine development, three types of mRNA produced in the same manner as in Example [2-1], and mRNAs of Moderna and Pfizer-BioNTech produced through in vitro transcription after linearizing DNA using BsmBI (NEB) as a type IIS restriction enzyme similar to Example [2-1], were transfected into THP-1 cells (ATCC), which are representative antigen-presenting cells and monocyte-derived cells, or mouse DC2.4 cells (Merck), which are antigen-presenting immune cells and a dendritic cell lineage that plays an important role in muscle tissue, or cells activated by treating the DC2.4 cells with LPS (Activated DC2.4 Cells), and the activity of nanoluciferase was compared over time. As a result, as shown in B, C, and D of FIG. 6, it was confirmed that the three mRNA structures of the present invention generally exhibited expression efficiencies similar to or superior to those of Moderna and Pfizer-BioNTech, and it was confirmed that the high efficiency of the mRNA structures of the present invention was even more prominent in DC2.4 cells, and in particular, it was confirmed that the mRNA structure of CJ-1 exhibited the highest efficiency.

[0089] Furthermore, considering that the mRNA construct may be applied to gene therapy for muscle diseases, liver diseases, lung diseases, eye diseases, neurological diseases, etc. in the future, mRNA produced in the same manner as in Example [2-1] was transfected into C2C12 cells (ATCC) as representative muscle cells, Huh-7 cells (ATCC) and HepG2 cells (ATCC) as representative hepatocytes, A549 cells (ATCC) as representative lung cells, AREP-19 cells (ATCC) as representative retinal cells, SH-SY5Y cells (ATCC) and Neuro-2a cells (ATCC) as representative neural cells, and 293T cells, and the activity of nanoluciferase was compared over time. As a result, as shown in FIGS. 7 and 8, it was confirmed that the mRNA construct of the present invention exhibited high expression efficiency in all cells. In particular, the mRNA constructs of Moderna and Pfizer-BioNTech showed different expression patterns depending on the cells used, but the three mRNA constructs of the present invention were confirmed to consistently exhibit high expression efficiency regardless of the cell type.

[0090] Although the above has been described as an example of a preferred embodiment of the present invention, the scope of the present invention is not limited to the specific embodiments described above, and a person having ordinary skill in the relevant field will be able to make appropriate changes within the scope described in the claims of the present invention.

Claims

1. Base sequence encoding the target protein; The base sequence of the 3'-UTR of ζ-globin located downstream of the base sequence encoding the above target protein; and (A) located downstream of the base sequence of the 3'-UTR of the above ζ-globin 60 A base sequence comprising a repeating unit of G)n (wherein n is an integer from 1 to 3); An mRNA structure containing .

2. In claim 1, An mRNA structure wherein the base sequence of the above ζ-globin 3'-UTR includes the base sequence of sequence number 6.

3. In claim 1, Above (A 60 G) n An mRNA structure, wherein the base sequence containing the repeating unit comprises the base sequence of sequence number 21.

4. In claim 1, An mRNA structure further comprising a base sequence of an IRES (internal ribosome entry site) of EMCV (encephalomyocaditis virus) between the downstream base sequence encoding the target protein and the upstream base sequence of the 3'-UTR of ζ-globin.

5. In claim 4, An mRNA structure wherein the base sequence of the IRES of the above EMCV further includes the base sequence of sequence number 13.

6. In any one of claims 1 to 5, An mRNA structure further comprising, upstream of the base sequence encoding the target protein, a base sequence of a 5'-UTR of BBV (black beetle virus) or a base sequence of a 5'-UTR of PPRV (peste des petits ruminants virus).

7. In claim 6, The base sequence of the 5'-UTR of the above BBV includes the base sequence of sequence number 24, An mRNA structure wherein the base sequence of the 5'-UTR of the above PPRV includes the base sequence of SEQ ID NO: 25 or the base sequence of SEQ ID NO:

26.

8. In claim 6, An mRNA structure comprising a base sequence of the 5'-UTR of BBV, upstream of a base sequence encoding the target protein.

9. In claim 6, The mRNA structure is an mRNA structure for transfection into cells.

10. A pharmaceutical composition for preventing or treating a microbial infectious disease, comprising the mRNA structure of claim 1.

11. In claim 10, A pharmaceutical composition wherein the above pharmaceutical composition is a vaccine.

12. A pharmaceutical composition for preventing or treating cancer or a genetic disease, comprising the mRNA structure of claim 1.

13. In claim 12, The pharmaceutical composition above is a pharmaceutical composition that is a gene therapy agent.

Citation Information

Patent Citations

  • Ground settlement measuring apparatus

    KR1020220141715A

  • Gamma correction method for improved quality of the reconstructed hologram in the full-color hologram display

    KR102746960B1